Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report issued on Wednesday, AnalystRatings.com reports. They currently have a $70.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 180.00% from the stock’s current price.
STOK has been the subject of a number of other reports. Cantor Fitzgerald cut their target price on Stoke Therapeutics from $76.00 to $68.00 and set an “overweight” rating for the company in a research report on Tuesday, August 17th. Zacks Investment Research upgraded Stoke Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 22nd. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $63.63.
Shares of NASDAQ STOK opened at $25.00 on Wednesday. The stock has a 50 day simple moving average of $27.11 and a 200-day simple moving average of $33.76. The company has a market cap of $918.73 million, a PE ratio of -13.23 and a beta of 0.27. Stoke Therapeutics has a 12-month low of $23.22 and a 12-month high of $71.58.
In other Stoke Therapeutics news, COO Huw M. Nash sold 5,700 shares of the company’s stock in a transaction on Wednesday, September 1st. The stock was sold at an average price of $26.00, for a total value of $148,200.00. Following the transaction, the chief operating officer now owns 5,700 shares of the company’s stock, valued at $148,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Barry Ticho sold 43,166 shares of the company’s stock in a transaction on Tuesday, July 13th. The shares were sold at an average price of $32.75, for a total value of $1,413,686.50. The disclosure for this sale can be found here. Insiders sold 54,566 shares of company stock worth $1,726,446 in the last ninety days. 51.80% of the stock is owned by corporate insiders.
Large investors have recently made changes to their positions in the business. O Shaughnessy Asset Management LLC acquired a new stake in Stoke Therapeutics during the 1st quarter valued at $25,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Stoke Therapeutics during the 1st quarter valued at $37,000. Ameritas Investment Partners Inc. raised its stake in Stoke Therapeutics by 38.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,497 shares of the company’s stock valued at $50,000 after purchasing an additional 418 shares during the period. Royal Bank of Canada raised its stake in Stoke Therapeutics by 1,593.5% during the 1st quarter. Royal Bank of Canada now owns 1,304 shares of the company’s stock valued at $51,000 after purchasing an additional 1,227 shares during the period. Finally, E Fund Management Co. Ltd. acquired a new stake in Stoke Therapeutics during the 1st quarter valued at $56,000. 55.00% of the stock is currently owned by institutional investors.
About Stoke Therapeutics
Stoke Therapeutics, Inc is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
Featured Article: Understanding the different types of bonds
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.